La cadena de opciones muestra datos clave de las opciones de acciones de DeFi Development Corp a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para DeFi Development Corp..

DeFi Development Corp (NASDAQ:JNVR) Bolsa, Cadena de Opciones

Janover

Cryptocurrency,Concept.,A,Macro,Shot,Of,Solana,Cryptocurrency,Coin,In

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

JNVR

Solana sube 43 % en 30 días. Airdrop del token SNS, apoyo institucional y posible impacto de la Fed marcan el rumbo de SOL.

Solana (SOL) sube 43% en un mes: nuevo token SNS, apoyo institucional y posible rally tras la Fed

DeFi Development Corp

WIIM

STVN

Stevanato Group shares are trading higher after the company reported a year-over-year increase in Q1 sales results.

Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares are trading higher on Thursday. The company disclosed that Taiwan-based <a href="https://www.benzinga.com/pressreleases/25/05/n45277580/china-airlines-announces-order-for-boeing-777x-passenger-and-freighter-models">China Airlines</a> has ordered 14 Boeing 777X wide-body aircraft.
China Airlines placed an order for ten 777-9 passenger aircraft and four 777-8 Freighter airplanes. This order, which was booked in March 2025, also includes options for an additional five 777-9s and four 777-8 Freighters.
Notably, China Airlines is the first airline in Taiwan to order the fuel-efficient 777X. The airline will utilize the widebody jets&#8217; increased capacity and extended range on its long-haul routes connecting Taiwan with North America and Europe.
Also Read: <a href="https://www.benzinga.com//node/44888512">Boeing Jet Returns To US Amid Escalating Tariff Tensions With China</a>
Kao Shing-Hwang, chairman of China Airlines said, &#8220;The advanced technology and features of the 777-9 will provide our customers with the best-in-class flying experience, while the 777-8 Freighter&#8217;s range and fuel-efficiency will enable us to maintain a leadership position in air cargo.&#8221;
Dan Schull, Boeing vice president of Commercial Sales,&nbsp;Northeast Asia added, &#8220;Operating the 777-9 and 777-8 Freighter will allow China Airlines to add capacity and position the airline for further growth going&nbsp;forward.&#8221;&nbsp;
In April, Boeing reported first-quarter revenue of $19.496 billion, beating the consensus of $19.43 billion and adjusted loss per share of 0.49 cents beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44948499/boeing-stock-jumps-after-q1-2025-results-production-expansion-plans-for-737-and-787" rel="noreferrer noopener">consensus of a $1.27 loss per share</a>.
The company booked 221 net orders and delivered 130 commercial airplanes, with a backlog of over 5,600 planes valued at <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">$460 billion in the quarter</a>.
On April 23, 2025, Boeing CEO Kelly Ortberg <a href="https://www.benzinga.com//node/44960098">confirmed</a> that China has stopped taking delivery of Boeing aircraft due to escalating trade tensions and high tariffs between the U.S. and China.
The halt in Boeing&#8217;s China deliveries came after President Donald Trump raised tariffs on Chinese goods to 145%. China retaliated with 125% tariffs on U.S.-made goods, including aircraft, which made Boeing planes significantly less affordable for Chinese customers.
The ban has drawn the attention of President Donald Trump toward Boeing. The company's significant role in China's retaliation strategy has been highlighted by <a href="https://www.benzinga.com//node/44837703">Bank of America (BofA) aerospace and defense analyst Ronald Epstein</a>, Fortune reported.
Epstein stated that Boeing is the U.S.'s largest exporter and is not surprised by China's move; however, they viewed the situation as ‘unsustainable.' &#8220;When considering balances of trade, we think the Trump Administration can&#8217;t ignore Boeing," cautioned Epstein.
Investors can gain exposure to the stock via&nbsp;the iShares U.S. Aerospace &amp; Defense ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>) and Direxion Daily BA Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOEU#NASDAQ">BOEU</a>).
Price Action: BA shares are up 1.37% to $188.10 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45059743/china-open-to-co-operate-with-us-firms-voices-concern-over-trade-war-impact-as-tariffs-hits-chinese-airlines-and-boeing" target="_blank" rel="noreferrer noopener">China Breaks Silence On Tariff Impact, Says Trump Policies Are Hurting Its Airlines And Boeing</a></li>
</ul>
Image via Shutterstock

Asia

Equities

Large Cap

News

Emerging Markets

Contracts

BOEU

iShares Dow Jones US Aerospace & Defense Index Fund

Boeing Secures Order From Taiwan's China Airlines

Outset Medical shares are trading higher after the company reported better-than-expected Q1 sales results.

PRVA

Privia Health Group shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

LPRO

Open Lending shares are trading higher. The company reported Q1 financial results.

Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) with a Neutral and lowers the price target from $15 to $13.

Price Target

Analyst Ratings

RCUS

Goldman Sachs Maintains Neutral on Arcus Biosciences, Lowers Price Target to $13

Maximus shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.

PBPB

Potbelly shares are trading higher after the company reported better-than-expected Q1 sales results.

QTWO

Q2 Holdings shares are trading higher following better-than-expected Q1 financial results and issued Q2 sales guidance above the estimate. Additionally, Stifel and Baird raised their respective price targets on the stock.

KRMD

KORU Medical Systems shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY25 sales guidance above estimates.

Goldman Sachs analyst Jamie Perse maintains Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) with a Neutral and raises the price target from $2.5 to $5.

Goldman Sachs Maintains Neutral on Agilon Health, Raises Price Target to $5

F&G Annuities & Life shares are trading lower after the company reported Q1 financial results and missed its adjusted EPS and revenue estimates.

ACAD

ACADIA Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.

BLZE

Backblaze shares are trading higher after the company reported better-than-expected Q1 financial results.

RVMD

Revolution Medicines shares are trading higher after Oppenheimer raised its price target on the stock from $70 to $75.

Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) has outperformed the market over the past 5 years by 8.03% on an annualized basis producing an average annual return of 22.54%. Currently, Corteva has a market capitalization of $43.88 billion. 
Buying $100 In CTVA: If an investor had bought $100 of CTVA stock 5 years ago, it would be worth $263.49 today based on a price of $64.24 for CTVA at the time of writing.
<h3>Corteva's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746715545_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CTVA

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Openlane shares are trading higher after the company reported better-than-expected Q1 financial results.

Oppenheimer analyst Ian Zaffino maintains Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Outperform and raises the price target from $65 to $85.

Oppenheimer Maintains Outperform on Turning Point Brands, Raises Price Target to $85

INGN

Inogen shares are trading lower after the company reported Q1 financial results and issued Q2 sales guidance below estimates. Also, Stifel maintained a Hold rating on the stock and lowered its price target from $10 to $7.

First Advantage shares are trading higher after the company reported better-than-expected Q1 financial results.

Press Releases

DeFi Development Corporation Purchases Approximately $11.5 Million of Solana (SOL) as Part of New Treasury Strategy

DeFi Development Corporation to Host X Spaces Event with Industry Leaders: "Scaling Solana: Builders, Backers, & Believers"

DeFi Development Corporation Appoints John Han as Chief Financial Officer

DeFi Development Corporation Adds $9.9M in Solana to Treasury

DeFi Development Corp. Announces $24 Million Private Placement to Accelerate Solana Accumulation Strategy

DeFi Development Corp. Announces Ticker Symbol Change to "DFDV"

DeFi Dev Corp. Advances Solana Treasury Strategy with Validator Business Acquisition

DeFi Development Corp. Adds $11.2M in Solana to Treasury

DeFi Development Corp. Announces Seven-For-One Stock Split

Financing

DeFi Development Corp. Announces Closing of $24 Million Private Placement

AMBR

DFDV

Comments

DeFi Development Corp

DeFi Development Corp (JNVR) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL